Caribou Biosciences, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Caribou Biosciences, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $468.00K, a 0.00% change year-over-year.
- Caribou Biosciences, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $277.00K, a 12.60% increase year-over-year.
- Caribou Biosciences, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $6.00K, a 200.00% increase year-over-year.
- Caribou Biosciences, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-03-31 was $468.00K, a 29.84% decline year-over-year.
- Caribou Biosciences, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $745.00K, a 18.49% decline from fiscal 2024.
- Caribou Biosciences, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $914.00K, a 16.14% increase from fiscal 2023.
- Caribou Biosciences, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $787.00K, a 23.35% increase from fiscal 2022.
- Caribou Biosciences, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $638.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-03-31 | $468.00K 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $745.00K 10-K · filed 2026-03-05 | |
| 2025-09-30 | $277.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $6.00K 10-Q · filed 2025-11-12 | |
| 2025-03-31 | $468.00K 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $914.00K 10-K · filed 2026-03-05 | |
| 2024-09-30 | $246.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $2.00K 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $667.00K 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $787.00K 10-K · filed 2025-03-10 | |
| 2023-09-30 | $382.00K 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $404.00K 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $638.00K 10-K · filed 2024-03-11 | |
| 2022-03-31 | $361.00K 10-Q · filed 2023-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |